{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:20:57Z","timestamp":1782080457349,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170186, 82170166, 82370193, 81720108002"],"award-info":[{"award-number":["82170186, 82170166, 82370193, 81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170186, 82170166, 82370193, 81720108002"],"award-info":[{"award-number":["82170186, 82170166, 82370193, 81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170186, 82170166, 82370193, 81720108002"],"award-info":[{"award-number":["82170186, 82170166, 82370193, 81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170186, 82170166, 82370193, 81720108002"],"award-info":[{"award-number":["82170186, 82170166, 82370193, 81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of National Key Clinical Specialty, Jiangsu Provincial Special Program of Medical Science","award":["BE2023775"],"award-info":[{"award-number":["BE2023775"]}]},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education","award":["ZDXK202209"],"award-info":[{"award-number":["ZDXK202209"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M691336"],"award-info":[{"award-number":["2021M691336"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010246","name":"Postdoctoral Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["2021K083A"],"award-info":[{"award-number":["2021K083A"]}],"id":[{"id":"10.13039\/501100010246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-025-01542-7","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T13:53:10Z","timestamp":1748699590000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Jiahao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"1542_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/ppo.0000000000000449","volume":"26","author":"CE Correia","year":"2020","unstructured":"Correia CE, Schaff LR, Grommes C (2020) Central nervous system lymphoma: approach to diagnosis and treatment. Cancer J 26:241\u2013252. https:\/\/doi.org\/10.1097\/ppo.0000000000000449","journal-title":"Cancer J"},{"key":"1542_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/0284186x.2016.1270465","volume":"56","author":"G Enblad","year":"2017","unstructured":"Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundstr\u00f6m C, Amini RM, Hagberg H (2017) Population-based experience on primary central nervous system lymphoma 2000\u20132012: the incidence is increasing. Acta Oncol 56:599\u2013607. https:\/\/doi.org\/10.1080\/0284186x.2016.1270465","journal-title":"Acta Oncol"},{"key":"1542_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/s0360-3016(01)01639-x","volume":"51","author":"M Reni","year":"2001","unstructured":"Reni M, Ferreri AJ, Guha-Thakurta N, Blay JY, Dell\u2019Oro S, Biron P, Hochberg FH (2001) Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys 51:419\u2013425. https:\/\/doi.org\/10.1016\/s0360-3016(01)01639-x","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1542_CR4","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/s2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros\u00e9e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud\u00e0 R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, G\u00f8rl\u00f8v JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217-227. https:\/\/doi.org\/10.1016\/s2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"1542_CR5","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/s0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520. https:\/\/doi.org\/10.1016\/s0140-6736(09)61416-1","journal-title":"Lancet"},{"key":"1542_CR6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/bloodadvances.2021004212","volume":"6","author":"I Bonzheim","year":"2022","unstructured":"Bonzheim I, Sander P, Salmer\u00f3n-Villalobos J, S\u00fcsskind D, Szurman P, Gekeler F, Spitzer MS, Steinhilber J, Kohler E, B\u00fcssgen M, Schittenhelm J, Salaverria I, Campo E, Coupland SE, Quintanilla-Martinez L, Fend F (2022) The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv 6:1598\u20131607. https:\/\/doi.org\/10.1182\/bloodadvances.2021004212","journal-title":"Blood Adv"},{"key":"1542_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","volume":"19","author":"TA Ollila","year":"2018","unstructured":"Ollila TA, Olszewski AJ (2018) Extranodal diffuse large B cell lymphoma: Molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol 19:38. https:\/\/doi.org\/10.1007\/s11864-018-0555-8","journal-title":"Curr Treat Options Oncol"},{"key":"1542_CR8","first-page":"830","volume":"20","author":"GO Cetin","year":"2016","unstructured":"Cetin GO, Baris IC, Caner V, Sarikepe B, Sen Turk N, Tepeli E, Hacioglu S, Sari I, Bagci G, Keskin A (2016) Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin\u2019s lymphomas: novel CD79B variations have been revealed. Eur Rev Med Pharmacol Sci 20:830\u2013836","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1542_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"key":"1542_CR10","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.1002\/cam4.3499","volume":"9","author":"F Chen","year":"2020","unstructured":"Chen F, Pang D, Guo H, Ou Q, Wu X, Jiang X, Wei X, Liu S, Huang L, Liang Z, Zhou D, Li W (2020) Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: a real-world experience of off-label ibrutinib use. Cancer Med 9:8676\u20138684. https:\/\/doi.org\/10.1002\/cam4.3499","journal-title":"Cancer Med"},{"key":"1542_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH (2017) Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31:833-843.e835. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.012","journal-title":"Cancer Cell"},{"key":"1542_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/ejh.13667","volume":"107","author":"L Renaud","year":"2021","unstructured":"Renaud L, Bossard JB, Carpentier B, Terriou L, Cambier N, Chanteau G, Escure G, Tilmont R, Barbieux S, Wemeau M, Hieulle J, Boyle EM, Morschhauser F (2021) Treatment with temozolomide and ibrutinib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol 107:370\u2013373. https:\/\/doi.org\/10.1111\/ejh.13667","journal-title":"Eur J Haematol"},{"key":"1542_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bjh.16946","volume":"192","author":"KL Lewis","year":"2021","unstructured":"Lewis KL, Chin CK, Manos K, Casey J, Hamad N, Crawford J, Ho SJ, Issa S, Grigg A, Wood P, Gandhi MK, Do B, Nastoupil L, Hawkes EA, Cheah CY (2021) Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance\/MD Anderson Cancer Center experience. Br J Haematol 192:1049\u20131053. https:\/\/doi.org\/10.1111\/bjh.16946","journal-title":"Br J Haematol"},{"key":"1542_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Molu\u00e7on-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonni\u00e8re M, El Yamani A, Ghesqui\u00e8res H, Hoang-Xuan K (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer 117:121\u2013130. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.024","journal-title":"Eur J Cancer"},{"key":"1542_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-140172","volume":"136","author":"Y Song","year":"2020","unstructured":"Song Y, Xu W, Song Y, Liu L, Lin S, Li Z, Liu T, Yi S, Zhou D, Zhang M, Hu Y, Jin J, Zhu H, Lu Z, Zhao R, Xu Z, Zhu J (2020) Pooled analysis of safety data from clinical trials of orelabrutinib monotherapy in hematologic malignancies. Blood 136:43\u201343. https:\/\/doi.org\/10.1182\/blood-2020-140172","journal-title":"Blood"},{"key":"1542_CR16","doi-asserted-by":"publisher","first-page":"CT132","DOI":"10.1158\/1538-7445.Am2020-ct132","volume":"80","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhao R, Liang R, Gao Y, Liu R, Chen X, Lu Z, Wang Z, Yu L, Shakib S, Cui J (2020) Abstract CT132: Orelabrutinib, a potent and selective Bruton\u2019s tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties. Cancer Res 80:CT132\u2013CT132. https:\/\/doi.org\/10.1158\/1538-7445.Am2020-ct132","journal-title":"Cancer Res"},{"key":"1542_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","volume":"21","author":"H Yu","year":"2021","unstructured":"Yu H, Wang X, Li J, Ye Y, Wang D, Fang W, Mi L, Ding N, Wang X, Song Y, Zhu J (2021) Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther Oncolytics 21:158\u2013170. https:\/\/doi.org\/10.1016\/j.omto.2021.03.015","journal-title":"Mol Ther Oncolytics"},{"key":"1542_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1212\/wnl.0000000000000593","volume":"83","author":"M Holdhoff","year":"2014","unstructured":"Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X (2014) High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 83:235\u2013239. https:\/\/doi.org\/10.1212\/wnl.0000000000000593","journal-title":"Neurology"},{"key":"1542_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/ajh.24204","volume":"90","author":"R Kansara","year":"2015","unstructured":"Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D (2015) Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol 90:1149\u20131154. https:\/\/doi.org\/10.1002\/ajh.24204","journal-title":"Am J Hematol"},{"key":"1542_CR20","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.3892\/ol.2016.4393","volume":"11","author":"KI Ly","year":"2016","unstructured":"Ly KI, Crew LL, Graham CA, Mrugala MM (2016) Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: a single-institution experience. Oncol Lett 11:3471\u20133476. https:\/\/doi.org\/10.3892\/ol.2016.4393","journal-title":"Oncol Lett"},{"key":"1542_CR21","doi-asserted-by":"publisher","first-page":"21541","DOI":"10.1038\/s41598-022-24922-y","volume":"12","author":"X Yuan","year":"2022","unstructured":"Yuan X, Yu T, Huang Y, Jiang H, Xu X, Liang Y, Qian W (2022) Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma. Sci Rep 12:21541. https:\/\/doi.org\/10.1038\/s41598-022-24922-y","journal-title":"Sci Rep"},{"key":"1542_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT (2023) Primary central nervous system lymphoma. Nat Rev Dis Primers 9:29. https:\/\/doi.org\/10.1038\/s41572-023-00439-0","journal-title":"Nat Rev Dis Primers"},{"key":"1542_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20:687\u2013694. https:\/\/doi.org\/10.1093\/neuonc\/nox187","journal-title":"Neuro Oncol"},{"key":"1542_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","volume":"34","author":"I Hern\u00e1ndez-Verdin","year":"2023","unstructured":"Hern\u00e1ndez-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, Lerintiu F, Uro-Coste E, Oberic L, Figarella-Branger D, Chinot O, Gauchotte G, Taillandier L, Marolleau JP, Polivka M, Adam C, Ursu R, Schmitt A, Barillot N, Nichelli L, Lozano-S\u00e1nchez F, Iba\u00f1ez-Juli\u00e1 MJ, Peyre M, Mathon B, Abada Y, Charlotte F, Davi F, Stewart C, de Reyni\u00e8s A, Choquet S, Soussain C, Houillier C, Chapuy B, Hoang-Xuan K, Alentorn A (2023) Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol 34:186\u2013199. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.002","journal-title":"Ann Oncol"},{"key":"1542_CR25","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","volume":"13","author":"J Radke","year":"2022","unstructured":"Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, Uhrig S, H\u00fcbschmann D, Toprak UH, L\u00f3pez C, Hostench XP, Borgoni S, Juraeva D, Pritsch F, Paramasivam N, Balasubramanian GP, Schlesner M, Sahay S, Weniger M, Pehl D, Radbruch H, Osterloh A, Korfel A, Misch M, Onken J, Faust K, Vajkoczy P, Moskopp D, Wang Y, J\u00f6dicke A, Tr\u00fcmper L, Anagnostopoulos I, Lenze D, K\u00fcppers R, Hummel M, Schmitt CA, Wiestler OD, Wolf S, Unterberg A, Eils R, Herold-Mende C, Brors B, Siebert R, Wiemann S, Heppner FL (2022) The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun 13:2558. https:\/\/doi.org\/10.1038\/s41467-022-30050-y","journal-title":"Nat Commun"},{"key":"1542_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM (2018) A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature 560:387\u2013391. https:\/\/doi.org\/10.1038\/s41586-018-0290-0","journal-title":"Nature"},{"key":"1542_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1212\/wnl.0000000000003420","volume":"88","author":"K Chamoun","year":"2017","unstructured":"Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C (2017) Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: a retrospective case series. Neurology 88:101\u2013102. https:\/\/doi.org\/10.1212\/wnl.0000000000003420","journal-title":"Neurology"},{"key":"1542_CR28","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.Ccr-24-0605","volume":"30","author":"C Grommes","year":"2024","unstructured":"Grommes C, Nandakumar S, Schaff LR, Gavrilovic I, Kaley TJ, Nolan CP, Stone J, Thomas AA, Tang SS, Wolfe J, Bozza A, Wongchai V, Hyde A, Barrett E, Lynch EA, Madzsar JT, Lin A, Piotrowski AF, Pentsova E, Francis JH, Hatzoglou V, Schultz N, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK (2024) A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma. Clin Cancer Res 30:4005\u20134015. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0605","journal-title":"Clin Cancer Res"},{"key":"1542_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.Cd-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK (2017) Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7:1018\u20131029. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0613","journal-title":"Cancer Discov"},{"key":"1542_CR30","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1182\/blood-2021-147742","volume":"138","author":"Y Guo","year":"2021","unstructured":"Guo Y, Lan X, Chang X, Wang G, Zou D, Su L, Sun W (2021) Ibrutinib in combination with rituximab and high-dose methotrexate in newly diagnosed primary central nervous system lymphoma patients. Blood 138:1416\u20131416. https:\/\/doi.org\/10.1182\/blood-2021-147742","journal-title":"Blood"},{"key":"1542_CR31","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1182\/blood-2022-165710","volume":"140","author":"S Zhao","year":"2022","unstructured":"Zhao S, Liu Y, Zhu Z, He J, Liu L, Wang X, Zhao Y, Hu C, Yuan X, Bai S, Geng Y, Huang W (2022) Orelabrutinib, rituximab, and high-dose methotrexate (HD-MTX) in newly diagnosed primary central nervous system lymphoma (PCNSL): a retrospective analysis on efficacy, safety, and biomarker. Blood 140:1338\u20131339. https:\/\/doi.org\/10.1182\/blood-2022-165710","journal-title":"Blood"},{"key":"1542_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11060-018-2970-x","volume":"140","author":"J Wu","year":"2018","unstructured":"Wu J, Duan L, Zhang L, Sun Z, Fu X, Li X, Li L, Wang X, Zhang X, Li Z, Yu H, Chang Y, Nan F, Yan J, Tian L, Wang X, Zhang M (2018) Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. J Neurooncol 140:427\u2013434. https:\/\/doi.org\/10.1007\/s11060-018-2970-x","journal-title":"J Neurooncol"},{"key":"1542_CR33","doi-asserted-by":"publisher","first-page":"1034668","DOI":"10.3389\/fonc.2022.1034668","volume":"12","author":"J Shen","year":"2022","unstructured":"Shen J, Liu J (2022) Bruton\u2019s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: a mini-review. Front Oncol 12:1034668. https:\/\/doi.org\/10.3389\/fonc.2022.1034668","journal-title":"Front Oncol"},{"key":"1542_CR34","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s10637-022-01219-5","volume":"40","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Wang WH, Dong M, Ma SS, Zhang XD, Zhu LN, Niu ST, Ding MJ, Zhang JM, Zhang L, Li X, Li L, Sun ZC, Wang XH, Fu XR, Li ZM, Chang Y, Nan FF, Yan JQ, Yu H, Wu XL, Zhou ZY, Zhang MZ (2022) Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. Invest New Drugs 40:650\u2013659. https:\/\/doi.org\/10.1007\/s10637-022-01219-5","journal-title":"Invest New Drugs"},{"key":"1542_CR35","doi-asserted-by":"publisher","first-page":"901797","DOI":"10.3389\/fonc.2022.901797","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C, Cui Y, Ren X, Li M, Yu K, Shen S, Jiang H, Li M, Zhang X, Zhao X, Zhu Q, Lin S (2022) Orelabrutinib combined with lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol 12:901797. https:\/\/doi.org\/10.3389\/fonc.2022.901797","journal-title":"Front Oncol"},{"key":"1542_CR36","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1002\/cncr.34985","volume":"129","author":"O Bairey","year":"2023","unstructured":"Bairey O, Taliansky A, Glik A, Amiel A, Yust-Katz S, Gurion R, Zektser M, Porges T, Sarid N, Horowitz NA, Shina TT, Lebel E, Cohen A, Geiger KR, Raanani P, Wolach O, Siegal T (2023) A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer 129:3905\u20133914. https:\/\/doi.org\/10.1002\/cncr.34985","journal-title":"Cancer"},{"key":"1542_CR37","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, Waultier-Rascalou A, di Blasi R, Houot R, Souchet L, Roos-Weil D, Uzunov M, Quoc SN, Jacque N, Boussen I, Gauthier N, Ouzegdouh M, Blonski M, Campidelli A, Ahle G, Guffroy B, Willems L, Corvilain E, Barrie M, Alcantara M, le Garff-Tavernier M, Psimaras D, Weiss N, Baron M, Bravetti C, Hoang-Xuan K, Davi F, Shor N, Alentorn A, Houillier C (2024) CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network. Am J Hematol 99:1240\u20131249. https:\/\/doi.org\/10.1002\/ajh.27316","journal-title":"Am J Hematol"},{"key":"1542_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood.2024024168","volume":"144","author":"JK Godfrey","year":"2024","unstructured":"Godfrey JK, Gao L, Shouse G, Song JY, Pak S, Lee B, Chen BT, Kallam A, Baird JH, Marcucci G, Ghoda L, Vauleon S, Danilov AV, Herrera AF, Kwak LW, Budde LE (2024) Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma. Blood 144:457\u2013461. https:\/\/doi.org\/10.1182\/blood.2024024168","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01542-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:07:22Z","timestamp":1753934842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01542-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1542"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01542-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}